Agreement - October 3, 2019
Genmab enters into agreement with Tempus
Genmab has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The multi-year collaboration will combine Tempus’ sequencing capabilities and platform of integrated clinical and molecular data with Genmab’s translational, biomarker and target discovery expertise, they state. The companies will […]
Agreement - September 30, 2019
Bactiguard signs global license agreement
The company has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization. “Our new, global partnership has […]
Agreement - September 17, 2019
Inficure Bio in major US deal
Inficure Bio has recently signed an agreement with a publicly listed pharmaceutical manufacturer in the US. The deal is twice as large as the previous record-breaking deal signed last spring with a company in Switzerland. “This is a fantastic opportunity for us. Deals like this demonstrate that our international credibility is increasing”, says Sofia Mayans, […]
Agreement - September 16, 2019
Novo Nordisk and Medtronic enter agreement
The two companies have announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic. This new, non-exclusive collaboration reflects both companies′ commitment to making diabetes management easier by integrating key health technologies, they state. “Millions of people living […]
Agreement - September 5, 2019
Orexo signs partnership agreement with GAIA to develop and commercialize a new digital therapy
Orexo has entered into an exclusive agreement with GAIA for a new digital therapy (DTx) for the treatment of Opioid Use Disorder (OUD). Orexo will have the exclusive global commercial rights to the product and intends to launch it in the US in 2022, subject to regulatory approval. “We are delighted to sign this partnership […]
Agreement - September 4, 2019
Zealand Pharma and Boehringer Ingelheim initiate Phase 2 development of BI 456906
Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. Potential as […]
